induced pluripotent stem cells

What are induced pluripotent stem cells or IPS cells & clinical prospects?

induced pluripotent stem cells clinical trials map

Induced pluripotent stem cells or IPS cells just might be the most exciting development in the stem cell field over the last 15 years. They have unique potential for clinical impact for regenerative medicine too, both through their use to produce differentiated cellular therapies and indirectly via disease modeling as well as drug screening. The …

What are induced pluripotent stem cells or IPS cells & clinical prospects? Read More »

Regenerative medicine recommended reads including $191 million to researcher

Mark-Pennesi-CRISPR-regenerative-medicine-eye

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as …

Regenerative medicine recommended reads including $191 million to researcher Read More »

Japan conditionally approves new IPS cell-based heart study

Yoshiki-Sawa-IPS-cells-stem-cells-heart-diseease

Where do things stand with IPS cell translational research? The newest development is that regulators in Japan just have given conditional approval to an Osaka University team to an induced pluripotent stem (IPS) cell-based study for ischemic heart disease. For years IPS cell-based products have been on-again off-again in active clinical study for macular degeneration, work …

Japan conditionally approves new IPS cell-based heart study Read More »

Journal club: Jaenisch lab paper on epigenetic CRISPR-Cas9 rescue of Fragile X in a dish

Liu-et-al.-Figure-6C-Fragile-X-CRISPR-Cell-e1519673510685

There’s much more to CRISPR-Cas9 than just gene editing and a new paper from the lab of Rudy Jaenisch in Cell highlights that in an exciting way. It reports epigenetic reversal of a Fragile X Syndrome phenotype in induced pluripotent stem cell (IPSC) neurons. Fragile X Syndrome is a neurological disorder in boys resulting from CGG repeat …

Journal club: Jaenisch lab paper on epigenetic CRISPR-Cas9 rescue of Fragile X in a dish Read More »

Adverse event in IPS cell (ips細胞) trial for vision loss in Japan: initial perspectives

Takahashi-IPS-transplant

A team of researchers at RIKEN and Kobe City Medical Center reported at a press conference today a serious adverse event in a clinical trial participant receiving an induced pluripotent stem cell (IPS cell)-based therapy for vision loss. According to Japan Times and Yahoo! Japan (in Japanese), the patient in question in the IPS cell …

Adverse event in IPS cell (ips細胞) trial for vision loss in Japan: initial perspectives Read More »

Interview with Bioheart CSO, Kristin Comella including on FDA

Kristin-Comella1

I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem …

Interview with Bioheart CSO, Kristin Comella including on FDA Read More »

Was Fujifilm CDI acquisition a good move by the companies?

Fujifilm-Logo

The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did …

Was Fujifilm CDI acquisition a good move by the companies? Read More »

Masayo Takahashi Interview on iPS cells, clinical studies, & more

Masayo-Takahashi

In the interview below I talk with Dr. Masayo Takahashi, who is leading a team conducting the first ever in-human clinical study based on iPS cells. The work began with patient enrollment on Aug. 1, 2013 in Japan. 1. Can you tell us a bit about your background? As an M.D./Ph.D. and ophthalmologist do you …

Masayo Takahashi Interview on iPS cells, clinical studies, & more Read More »